Idebenone, a new drug
in the treatment of cognitive impairment in patients with dementia of the
Bergamasco B, Scarzella L, La Commare P.
III Neurological Clinic,
University of Turin, Italy.
Funct Neurol 1994 May-Jun;9(3):161-8
Alzheimer's disease (AD) is a
central nervous system disorder characterized by the presence of
neurofibrillary tangles, neuritic plaques and dystrophic neurones in
susceptible areas of the brain. Few options for treatment of AD symptomatology
are available. We conducted a multicenter, randomized, double-blind,
placebo-controlled, parallel trial consisting of a 90 day treatment period
followed by a 30 day single blind placebo administration and by an optional
long term period of treatment up to a year with idebenone in open fashion.
Ninety two patients entered the study and nine of them dropped out before the
first control. Treatment with idebenone was found effective on memory,
attention, and orientation and in slowing down the natural progressive
worsening of the disease. The most common side effects associated with this
treatment were insomnia, gastralgia, nausea, and anxiety. However, all adverse
effects were of mild intensity and did not require specific therapies.